We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nkarta Inc (NKTX) USD0.0001

Sell:$12.07 Buy:$12.08 Change: $1.20 (11.04%)
NASDAQ:0.90%
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
Sell:$12.07
Buy:$12.08
Change: $1.20 (11.04%)
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
Sell:$12.07
Buy:$12.08
Change: $1.20 (11.04%)
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. The Company’s product candidates include NKX101 and NKX019, which are in ongoing Phase I clinical trials. NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors. It is engineered with a chimeric antigen receptor (CAR) targeting NKG2D ligands on tumor cells. NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed CAR for enhanced tumor cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support.

Contact details

Address:
1150 Veterans Boulevard
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (925) 4071049
Website:
https://www.nkartatx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NKTX
ISIN:
US65487U1088
Market cap:
$561.39 million
Shares in issue:
49.07 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Paul Hastings
    President, Chief Executive Officer, Director
  • Alyssa Levin
    Chief Financial and Business Officer
  • Ralph Brandenberger
    Chief Technical Officer
  • James Trager
    Chief Scientific Officer
  • David Shook
    Chief Medical Officer
  • Alicia Hager
    Corporate Secretary, Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.